Advanced / High‑Dose Protocol (2.0 mL = 5.0 mg/mL)
| Week | Weekly Dose | Units (per measurement) (mL) | Notes |
|---|---|---|---|
| Weeks 1–4 | 5 mg (5,000 mcg) | 100 units (1.00 mL) | 0.5 vials |
| Weeks 5–8 | 7.5 mg (7,500 mcg) | 150 units (1.50 mL) | 0.75 vials |
| Weeks 9–12+ | 10 mg (10,000 mcg) | 200 units (2.00 mL) | 1 vial |
Caution: High‑dose protocols (7.5–10 mg weekly) have been explored in phase 1b research but require careful monitoring and clinical oversight.[1] Doses above 6 mg increase the risk of gastrointestinal observations. The 2.0 mL reconstitution provides higher concentration to reduce measurement volume. For doses requiring >3.0 mL total volume, split into two separate measurements at different sites.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
How This Works
Mazdutide functions as a dual agonist at both GLP‑1 and glucagon receptors, combining the appetite‑suppressing and glucose‑lowering effects of GLP‑1 with the energy‑expenditure benefits of glucagon activation.[2][6] This dual mechanism distinguishes it from single‑target GLP‑1 agonists and has shown robust weight loss efficacy in clinical trials. Phase 2 studies demonstrated 6.7–11.3% body weight reduction at 3–6 mg weekly doses over 24 weeks.[2] A 48‑week phase 3 trial reported sustained weight loss of 11–14% with 4–6 mg weekly maintenance.[3] In type 2 diabetes populations, mazdutide achieved meaningful HbA1c reductions (~1.7%) alongside ~7% weight loss.[4] The extended half‑life enables convenient once‑weekly measurement with steady pharmacologic exposure.